A single-arm, multi-center, real-world study of Keverprazan for the treatment of reflux esophagitis in China

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400089974

Enrollment

Unknown

Registered

2025-04-03

Start date

2025-02-28

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients diagnosed with reflux esophagitis

Interventions

Keverprazan group:None

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Participants must be 18 years of age or older, with no gender restrictions. 2. Diagnosed with reflux esophagitis by a clinical physician (confirmed endoscopically within 1 year prior to initiating Keverprazan treatment). 3. Participants have received, are currently receiving, or are planning to receive Keverprazan treatment. 4. Participants have been informed of all study requirements, are willing to participate, and have signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Intolerance to Keverprazan and its excipient components. 2. Contraindications for the use of Keverprazan as per the instructions.

Design outcomes

Primary

Measure	Time frame
Percentage of participants with adverse events post-Keverprazan treatment;	—

Countries

China

Contacts

Public ContactJingyuan Fang

Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine

jingyuanfang@yahoo.com+86 21 58752345

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026